微创心通-B(02160):ENO™系列起搏器获CE批准LBBAP适应症

智通财经
May 10

智通财经APP讯,微创心通-B(02160)发布公告,近日,由本集团自主研发的ENO™系列心脏起搏器获CE批准左束支区域起搏(LBBAP)适应症。至此,本集团全系共六款CE认证起搏器均已获批LBBAP适应症。配以已实现商业化的FLEXIGO™3DLBBAP输送系统及VegaTMM58电极导线,本集团得以拥有LBBAP疗法的完整解决方案,可满足更多患者的临床需求,并进一步拓展收入来源。

LBBAP疗法为国际前沿生理性起搏技术,通过将电极精准植入左束支及其邻近区域,使电信号沿心脏天然传导系统传导,实现左右心室同步收缩,显著提升心脏泵血效率。该疗法更贴近生理起搏状态,可有效降低长期心室不同步所致心力衰竭风险,适用于心动过缓、传导阻滞等患者,显著改善患者生活质量与长期预后,是传统右心室起搏与双室起搏的重要升级与替代方案,在国内外指南中获得明确推荐,临床地位快速提升。

展望未来,本集团将依托心律管理业务逾60年在有源植入设备、远程监测、传感器算法领域的深厚积累,深度融合结构性心脏病业务在无源介入、输送系统、瓣膜设计、生物材料、血流动力学监测方面的技术优势,加快心力衰竭领域创新研发与全球商业化落地,致力于为全球患者提供覆盖心衰全病因、全阶段、全过程的创新综合器械管理方案,以更优质、更普惠的创新疗法惠及全球患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10